Trial 4P-17-5


A phase III, randomized, double-blind, placebo-controlled, multicenter trial testing Ipatasertib plus Abiraterone plus Prednisone/Prednisolone, relative to Placebo plus Abiraterone plus Prednisone/prednisolone in adult male patients with asymptomatic or mildly symptomatic, previously untreated, metastatic castrate-resistant prostate cancer

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Hormone, Other
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  David Quinn, M.D.
Other Trial Staff:  Cheryl Kefauver, Coordinator, Vage Movsesyan, D.M., Lagrimas Ilagan, D.M., Taison Tran, Coordinator, Honorina Enright, D.M., Amanda Luna, D.M., Brandi Scott, Coordinator, Charis Barg, Coordinator, Patrick Gilmore, Coordinator, Bartolo Santos, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.